Lack of ACTH/cortisol and GH responses to intravenously-infused substance P in Parkinson's disease

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Journal of Neural Transmission - Parkinsons Disease and Dementia Section

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF02261003PMID 7509607
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The hospital anxiety and depression scale.

  2014cited by this paper
• Plasma beta-lipotropin levels in Parkinson's disease

  2005cited by this paper
• Stimulation of ACTH/cortisol by intravenously infused substance P in normal men: inhibition by sodium valproate.

  1992cited by this paper
• Intravenously infused substance P enhances basal and growth hormone (GH) releasing hormone-stimulated GH secretion in normal men.

  1992cited by this paper
• Decreased levels of [Met]enkephalin, neuropeptide Y, substance P, and vasoactive intestinal peptide in parkinsonian adrenal medulla.

  1991cited by this paper
• Dopamine dependent decrease in enkephalin and substance P levels in basal ganglia regions of postmortem parkinsonian brains.

  1991cited by this paper
• Ventricular fluid neuropeptides in Parkinson's disease. II. Levels of substance P-like immunoreactivity.

  1991cited by this paper
• Substance P-containing neurons in the mesopontine tegmentum are severely affected in Parkinson's disease.

  1991cited by this paper
• Brain substance P receptors in Parkinson's disease.

  1990cited by this paper
• Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease.

  1990cited by this paper
• Adrenal grafting for Parkinson's disease: a role for substance P.

  1989cited by this paper
• Effects of substance P on experimental parkinsonian syndrome

  1989cited by this paper
• Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea.

  1988cited by this paper
• Parkinson's disease: an autoimmune process.

  1988cited by this paper
• [The anterior pituitary endocrine function in Parkinson's disease].

  1987cited by this paper
• Effect of dietary fiber on colonic cell proliferation and its relationship to colon carcinogenesis.

  1987cited by this paper
• Chemical neurotransmission in the parkinsonian brain.

  1987cited by this paper
• Dexamethasone suppression test in Parkinson's disease.

  1987cited by this paper
• Flushing and plasma substance P concentration during infusion of synthetic substance P in normal man.

  1986cited by this paper
• Effect of hypoglycaemia, TRH and levodopa on plasma growth hormone, prolactin, thyrotropin and cortisol in Parkinson's disease before and during therapy

  1986cited by this paper
• Dynamic testing in reproductive endocrinology.

  1986cited by this paper
• Pro-opiomelanocortin peptides in the human hypothalamus: comparative study between normal subjects and Parkinson patients.

  1985cited by this paper
• Immunocytochemical Studies of Substance P and Met‐Enkephalin in the Basal Ganglia and Substantia Nigra in Huntington's, Parkinson's and Alzheimer's Diseases

  1985cited by this paper
• Detection of the messenger RNAs coding for the opioid peptide precursors in pituitary and adrenal by "in situ' hybridization: study in several mammal species.

  1985cited by this paper
• Brain neurotransmitters and neuropeptides in Parkinson's disease.

  1984cited by this paper
• New separation method for monoclonal immunoradiometric assays and its application to assays for thyrotropin and human choriogonadotropin.

  1984cited by this paper
• Substance P immunoreactivity in the post-mortem parkinsonian brain.

  1984cited by this paper
• Methionine enkephalin, substance P, and homovanillic acid in the CSF of parkinsonian patients

  1984cited by this paper
• Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains.

  1983cited by this paper
• The Hospital Anxiety and Depression Scale

  1983cited by this paper
• Growth hormone and prolactin stimulation by Madopar in Parkinson's disease

  1981cited by this paper
• Role of striato-nigral substance P in the regulation of the activity of the nigro-striatal dopaminergic neurons.

  1980cited by this paper
• Spontaneous nocturnal plasma prolactin and growth hormone secretion in patients with Parkinson's disease and Huntington's chorea.

  1980cited by this paper
• Human corticotropin (ACTH) radioimmunoassay with synthetic 1--24 ACTH.

  1979cited by this paper
• Research diagnostic criteria: rationale and reliability.

  1978cited by this paper
• Direct solid-phase 125I radioimmunoassay of serum cortisol.

  1978cited by this paper
• Thyrotrophin releasing hormone--TSH.

  1977cited by this paper
• Dissociation of growth hormone and prolactin secretion in Parkinson's disease following chronic L-dopa therapy.

  1974cited by this paper
• A homologous radioimmunoassay for human prolactin.

  1973cited by this paper
• Simplified, partially automated method for radioimmunoassay of human thyroid-stimulating, growth, luteinizing, and follicle stimulating hormones.

  1967cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• Effects of Melatonin on the Behavioral Indices and Structural Characteristics of Cerebral and Spinal Neurons of Rats with Experimental Hemiparkinsonism

  2018cites this paper
• Effects of Melatonin on the Behavioral Indices and Structural Characteristics of Cerebral and Spinal Neurons of Rats with Experimental Hemiparkinsonism

  2018cites this paper
• Responses of Adenohypophyseal Hormones to Substance P Administration in Geldings: Comparison to Responses After Brief Exercise and Sulpiride Administration

  2016cites this paper
• Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?

  2015cites this paper
• The effect of glucocorticoids on bradykinesia induced by immobilization stress.

  2008cites this paper
• Pituitary-adrenal responses to dexamethasone and CRH administration in patients with untreated Parkinson’s disease

  1997cites this paper